# Durlobactam PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/durlobactam

> The FDA approved durlobactam, sponsored by Innoviva, Inc. (INVA), on May 23, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is durlobactam FDA approved?

Yes. The FDA approved durlobactam, sponsored by Innoviva, Inc. (INVA), on May 23, 2023. SEC Form 10-K: "XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use (formerly known as sulbactam-durlobactam or SUL-DUR), was approved by the FDA on May 23, 2023, and we commenced U.S. commercial sales of XACDURO® in the third quarter of 2023." [Calendar and source filings](https://sec-api.dev/pdufa/durlobactam)

Source: SEC Form 10-K, accession 0001193125-26-071776, https://www.sec.gov/Archives/edgar/data/1080014/000119312526071776/inva-20251231.htm (retrieved 2026-11-12). Last confirmed 2026-02-25. Cite: https://sec-api.dev/pdufa/durlobactam#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | durlobactam |
| Codes |  |
| Sponsor | Innoviva, Inc. (INVA) https://sec-api.dev/companies/inva/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### May 23, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-02-26, last confirmed 2026-02-25.
- SEC Form 10-K (accession 0001193125-26-071776): "XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use (formerly known as sulbactam-durlobactam or SUL-DUR), was approved by the FDA on May 23, 2023, and we commenced U.S. commercial sales of XACDURO® in the third quarter of 2023." https://www.sec.gov/Archives/edgar/data/1080014/000119312526071776/inva-20251231.htm
- SEC Form 10-K (accession 0000950170-25-027864): "XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use (formerly known as sulbactam-durlobactam or SUL-DUR), was approved by the FDA on May 23, 2023, and we commenced U.S. commercial sales of XACDURO® in the third quarter of 2023." https://www.sec.gov/Archives/edgar/data/1080014/000095017025027864/inva-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/durlobactam.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Durlobactam PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/durlobactam

```bibtex
@misc{secapidev_pdufa_durlobactam_20261116,
  title        = {Durlobactam PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/durlobactam}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_durlobactam_20261116","title":"Durlobactam PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/durlobactam","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
